Neil Hall – Pool/Getty Images
Thousands more Covid patients hospitalised across the NHS are set to receive the life-saving drug tocilizumab, following today’s results from the RECOVERY Trial.
“Roughly half of the patients who are in hospital with Covid would benefit from this treatment,” Prof Martin Landray, joint chief investigator of the trial, told Reaction.
In the large-scale study, run by Oxford University, over 4000 patients received the immunosuppressive drug, generally used to treat rheumatoid arthritis. Results suggested that tocilizumab could save one life for every 25 Covid patients on oxygen when used in addition to dexamethasone, a cheap steroid.